These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19947889)

  • 1. Receptor-mediated tumor targeting based on peptide hormones.
    Mezo G; Manea M
    Expert Opin Drug Deliv; 2010 Jan; 7(1):79-96. PubMed ID: 19947889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New approaches to the therapy of various tumors based on peptide analogues.
    Schally AV
    Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.
    Eberle AN; Mild G
    J Recept Signal Transduct Res; 2009; 29(1):1-37. PubMed ID: 19519167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting AAC-11 in cancer therapy.
    Faye A; Poyet JL
    Expert Opin Ther Targets; 2010 Jan; 14(1):57-65. PubMed ID: 20001210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer.
    Giblin MF; Veerendra B; Smith CJ
    In Vivo; 2005; 19(1):9-29. PubMed ID: 15796153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic cancer targeting peptides.
    Aina OH; Sroka TC; Chen ML; Lam KS
    Biopolymers; 2002; 66(3):184-99. PubMed ID: 12385037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT.
    Betzel T; Hess T; Waser B; Reubi JC; Roesch F
    Bioconjug Chem; 2008 Sep; 19(9):1796-802. PubMed ID: 18712900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormones, vitamins, and growth factors in cancer treatment and prevention. A critical appraisal.
    Lupulescu AP
    Cancer; 1996 Dec; 78(11):2264-80. PubMed ID: 8940995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
    Teplán I
    Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothalamic hormones and cancer.
    Schally AV; Comaru-Schally AM; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga JL; Halmos G
    Front Neuroendocrinol; 2001 Oct; 22(4):248-91. PubMed ID: 11587553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidates for peptide receptor radiotherapy today and in the future.
    Reubi JC; Mäcke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.